Fig. 1. Study design and SHIV infection dynamics.

a Experimental Design. Macaques infected with RT-SHIV (n = 4) were treated with daily tenofovir alafenamide/emtricitabine (FTC/TAF) and monthly intramuscular injections of cabotegravir and rilpivirine long-acting (CAB LA/RPV LA) 5 to 6 days after infection. Treatment was continued for six months followed by maintenance with CAB LA/RPV LA until month twelve. At month 30, macaques received an anti-CD8 monoclonal antibody MT807R1 to deplete CD8 + cells. b Acute SHIV viremia in treated (blue lines) and untreated (red lines) macaques. The thick lines denote median values. c SHIV RNA levels in treated (blue) and control (red) macaques during treatment (shaded blue area) and after treatment cessation. The crosses indicate the time of euthanasia. The horizontal dotted line denotes the limit of quantification (12.5 copies/mL). ART; antiretroviral therapy. Source data are provided as a Source Data file.